

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the Query Builder analysis.

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview

Query Builder Report: This report details the results of an analysis generated by the Sentinel Query Builder application. Query Builder enables FDA to visualize, draft, and create standardized medical product utilization queries examining dispensing patterns and cohort characteristics using a set of pre-defined parameters. This is a Type 5 (Medical Product Utilization) analysis as described in the Query Request Package (QRP) documentation. This is Report 1 of 2. This report includes all defined scenarios without baseline characteristics. For only scenarios with lipiodol and non-oil based agents and the applicable baseline characteristics, please see Report 2.

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) module, version 9.1.0.

Data Source: We executed this request on IBM® MarketScan® Commercial Claims and Encounters Database and Medicare Supplemental Database, which included 140 million members, on June 3, 2020. The study period included data from January 1, 2010 to December 31, 2018. Please see Appendix A for data availability dates.

Limitations: Algorithms used to define exposures and inclusion and exclusion criteria are imperfect; thus it is possible that there may be misclassification. Therefore, data should be interpreted with these limitations in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinelssystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel Query Builder, please refer to the documentation (<https://dev.sentinelssystem.org/projects/QB/repos/querybuilder/browse>).

Table of contents	
Table 1a	Descriptive statistics of cumulative exposure duration, all episodes, in days
Table 1b	Descriptive statistics of cumulative exposure duration, all episodes, in days, by sex
Table 1c	Descriptive statistics of cumulative exposure duration, all episodes, in days, by age group
Table 2a	Descriptive statistics of first exposure episode duration, in days
Table 2b	Descriptive statistics of first exposure episode duration, in days, by sex
Table 2c	Descriptive statistics of first exposure episode duration, in days, by age group
Table 3a	Descriptive statistics of all episode durations, in days
Table 3b	Descriptive statistics of all episode durations, in days, by sex
Table 3c	Descriptive statistics of all episode durations, in days, by age group
Table 4a	Descriptive statistics of days supplied per dispensing
Table 4b	Descriptive statistics of days supplied per dispensing, by sex
Table 4c	Descriptive statistics of days supplied per dispensing, by age group
Table 5a	Descriptive statistics of the length of all gaps between treatment episodes, in days
Table 5b	Descriptive statistics of the length of all gaps between treatment episodes, in days, by sex
Table 5c	Descriptive statistics of the length of all gaps between treatment episodes, in days, by age group
Table 6	Counts of reason for censoring, all episodes and first episode
Table 7	Cohort Attrition table
Appendix A	Dates of Available Data for Each Data Partner (DP) up to Request End Date (05/07/2020) as of Query Distribution Date
Appendix B	Specifications Used to Define Parameters in this Query
Appendix C	List of Generic and Brand Names of Medical Products Used to Define Index Exposure in this Request
Appendix D	List of Current Procedural Terminology, Fourth Edition (CPT-4) Codes Used to Define Exposures of Interest in this Request
Appendix E	List of Current Procedural Terminology, Fourth Edition (CPT-4) Codes Used to Define Inclusion Criteria in this Request

Table 1a. Descriptive statistics of cumulative exposure duration, all episodes, in days								
Exposures	Total Patients	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	1	1.00	-	1	1	1	1	1
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	12	3.92	8.34	1	1	1	2	30
Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	5,965,597	1.78	2.22	1	1	1	2	260
Ethiodized Oil, 0 Day Pre-Index Enrollment	2	1.00	0.00	1	1	1	1	1
Non-Oil Agents (All), 0 Day Pre-Index Enrollment	6,379	5.56	12.15	1	1	1	2	214
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	0	-	-	-	-	-	-	-
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	12	3.92	8.34	1	1	1	2	30
Non-Oil Agents (Omnipaque) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	8	1.75	1.75	1	1	1	2	6

Table 1b. Descriptive statistics of cumulative exposure duration, all episodes, in days, by sex								
Exposures	Total Patients	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	1	1.00	-	1	1	1	1	1
Female	1	1.00	-	1	1	1	1	1
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	12	3.92	8.34	1	1	1	2	30
Female	12	3.92	8.34	1	1	1	2	30
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-
Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	5,965,597	1.78	2.22	1	1	1	2	260
Female	5,959,413	1.78	2.22	1	1	1	2	260
Male	6,184	1.25	0.81	1	1	1	1	27
Other	0	-	-	-	-	-	-	-
Ethiodized Oil, 0 Day Pre-Index Enrollment	2	1.00	0.00	1	1	1	1	1
Female	2	1.00	0.00	1	1	1	1	1
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-
Non-Oil Agents (All), 0 Day Pre-Index Enrollment	6,379	5.56	12.15	1	1	1	2	214
Female	3,751	5.45	12.01	1	1	1	2	214
Male	2,628	5.71	12.34	1	1	1	2	180
Other	0	-	-	-	-	-	-	-
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	12	3.92	8.34	1	1	1	2	30
Female	12	3.92	8.34	1	1	1	2	30
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-
Non-Oil Agents (Omnipaque) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	8	1.75	1.75	1	1	1	2	6
Female	8	1.75	1.75	1	1	1	2	6
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-

Table 1c. Descriptive statistics of cumulative exposure duration, all episodes, in days, by age group								
Exposures	Total Patients	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	1	1.00	-	1	1	1	1	1
00-01 years	0	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-
15-18 years	0	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-
22-44 years	1	1.00	-	1	1	1	1	1
45-64 years	0	-	-	-	-	-	-	-
65-74 years	0	-	-	-	-	-	-	-
75+ years	0	-	-	-	-	-	-	-
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	12	3.92	8.34	1	1	1	2	30
00-01 years	0	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-
15-18 years	0	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-
22-44 years	6	1.83	2.04	1	1	1	1	6
45-64 years	5	1.20	0.45	1	1	1	1	2
65-74 years	1	30.00	-	30	30	30	30	30
75+ years	0	-	-	-	-	-	-	-
Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	5,965,597	1.78	2.22	1	1	1	2	260
00-01 years	191	1.08	0.37	1	1	1	1	4
02-04 years	130	1.22	1.17	1	1	1	1	12
05-09 years	412	1.08	0.74	1	1	1	1	15
10-14 years	7,412	1.34	1.03	1	1	1	1	21
15-18 years	107,030	1.57	1.27	1	1	1	2	39
19-21 years	214,935	1.56	1.29	1	1	1	2	65
22-44 years	3,449,120	1.95	2.71	1	1	1	2	260
45-64 years	2,006,519	1.55	1.23	1	1	1	2	184
65-74 years	126,206	1.50	1.16	1	1	1	2	32
75+ years	53,642	1.38	0.97	1	1	1	1	22
Ethiodized Oil, 0 Day Pre-Index Enrollment	2	1.00	0.00	1	1	1	1	1
00-01 years	0	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-

Table 1c. Descriptive statistics of cumulative exposure duration, all episodes, in days, by age group									
Exposures	Total Patients	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum	
15-18 years	0	-	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-	-
22-44 years	2	1.00	0.00	1	1	1	1	1	1
45-64 years	0	-	-	-	-	-	-	-	-
65-74 years	0	-	-	-	-	-	-	-	-
75+ years	0	-	-	-	-	-	-	-	-
Non-Oil Agents (All), 0 Day Pre-Index Enrollment	6,379	5.56	12.15	1	1	1	2	214	
00-01 years	9	3.00	2.50	1	1	2	4	7	
02-04 years	19	7.63	20.55	1	1	2	5	92	
05-09 years	21	7.57	13.50	1	1	2	8	53	
10-14 years	32	7.25	22.11	1	1	1	2	120	
15-18 years	59	5.66	14.17	1	1	1	2	93	
19-21 years	57	3.09	6.67	1	1	1	1	30	
22-44 years	976	5.45	12.40	1	1	1	2	214	
45-64 years	3,149	5.64	11.92	1	1	1	2	180	
65-74 years	1,197	5.88	13.01	1	1	1	2	153	
75+ years	860	4.96	10.79	1	1	1	2	94	
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	0	-	-	-	-	-	-	-	
00-01 years	0	-	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-	-
15-18 years	0	-	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-	-
22-44 years	0	-	-	-	-	-	-	-	-
45-64 years	0	-	-	-	-	-	-	-	-
65-74 years	0	-	-	-	-	-	-	-	-
75+ years	0	-	-	-	-	-	-	-	-
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	12	3.92	8.34	1	1	1	2	30	
00-01 years	0	-	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-	-
15-18 years	0	-	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-	-
22-44 years	6	1.83	2.04	1	1	1	1	6	
45-64 years	5	1.20	0.45	1	1	1	1	2	
65-74 years	1	30.00	-	30	30	30	30	30	

Table 1c. Descriptive statistics of cumulative exposure duration, all episodes, in days, by age group								
Exposures	Total Patients	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
75+ years	0	-	-	-	-	-	-	-
Non-Oil Agents (Omnipaque) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	8	1.75	1.75	1	1	1	2	6
00-01 years	0	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-
15-18 years	0	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-
22-44 years	5	2.00	2.24	1	1	1	1	6
45-64 years	3	1.33	0.58	1	1	1	2	2
65-74 years	0	-	-	-	-	-	-	-
75+ years	0	-	-	-	-	-	-	-

Table 2a. Descriptive statistics of first exposure episode duration, in days								
Exposures	Total Episodes	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	1	1.00	-	1	1	1	1	1
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	12	3.92	8.34	1	1	1	2	30
Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	5,965,597	1.01	0.07	1	1	1	1	15
Ethiodized Oil, 0 Day Pre-Index Enrollment	2	1.00	0.00	1	1	1	1	1
Non-Oil Agents (All), 0 Day Pre-Index Enrollment	6,379	4.21	9.39	1	1	1	1	180
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	0	-	-	-	-	-	-	-
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	12	3.92	8.34	1	1	1	2	30
Non-Oil Agents (Omnipaque) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	8	1.75	1.75	1	1	1	2	6

Table 2b. Descriptive statistics of first exposure episode duration, in days, by sex								
Exposures	Total Episodes	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	1	1.00	-	1	1	1	1	1
Female	1	1.00	-	1	1	1	1	1
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	12	3.92	8.34	1	1	1	2	30
Female	12	3.92	8.34	1	1	1	2	30
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-
Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	5,965,597	1.01	0.07	1	1	1	1	15
Female	5,959,413	1.01	0.07	1	1	1	1	15
Male	6,184	1.00	0.07	1	1	1	1	2
Other	0	-	-	-	-	-	-	-
Ethiodized Oil, 0 Day Pre-Index Enrollment	2	1.00	0.00	1	1	1	1	1
Female	2	1.00	0.00	1	1	1	1	1
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-
Non-Oil Agents (All), 0 Day Pre-Index Enrollment	6,379	4.21	9.39	1	1	1	1	180
Female	3,751	4.05	8.67	1	1	1	1	60
Male	2,628	4.43	10.32	1	1	1	1	180
Other	0	-	-	-	-	-	-	-
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	12	3.92	8.34	1	1	1	2	30
Female	12	3.92	8.34	1	1	1	2	30
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-
Non-Oil Agents (Omnipaque) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	8	1.75	1.75	1	1	1	2	6
Female	8	1.75	1.75	1	1	1	2	6
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-

Table 2c. Descriptive statistics of first exposure episode duration, in days, by age group								
Exposures	Total Episodes	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	1	1.00	-	1	1	1	1	1
00-01 years	0	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-
15-18 years	0	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-
22-44 years	1	1.00	-	1	1	1	1	1
45-64 years	0	-	-	-	-	-	-	-
65-74 years	0	-	-	-	-	-	-	-
75+ years	0	-	-	-	-	-	-	-
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	12	3.92	8.34	1	1	1	2	30
00-01 years	0	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-
15-18 years	0	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-
22-44 years	6	1.83	2.04	1	1	1	1	6
45-64 years	5	1.20	0.45	1	1	1	1	2
65-74 years	1	30.00	-	30	30	30	30	30
75+ years	0	-	-	-	-	-	-	-
Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	5,965,597	1.01	0.07	1	1	1	1	15
00-01 years	191	1.00	0.00	1	1	1	1	1
02-04 years	130	1.00	0.00	1	1	1	1	1
05-09 years	412	1.00	0.00	1	1	1	1	1
10-14 years	7,412	1.01	0.09	1	1	1	1	3
15-18 years	107,030	1.01	0.11	1	1	1	1	4
19-21 years	214,935	1.01	0.10	1	1	1	1	4
22-44 years	3,449,120	1.01	0.08	1	1	1	1	15
45-64 years	2,006,519	1.00	0.05	1	1	1	1	4
65-74 years	126,206	1.00	0.04	1	1	1	1	2
75+ years	53,642	1.00	0.05	1	1	1	1	2
Ethiodized Oil, 0 Day Pre-Index Enrollment	2	1.00	0.00	1	1	1	1	1
00-01 years	0	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-

Table 2c. Descriptive statistics of first exposure episode duration, in days, by age group									
Exposures	Total Episodes	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum	
15-18 years	0	-	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-	-
22-44 years	2	1.00	0.00	1	1	1	1	1	1
45-64 years	0	-	-	-	-	-	-	-	-
65-74 years	0	-	-	-	-	-	-	-	-
75+ years	0	-	-	-	-	-	-	-	-
Non-Oil Agents (All), 0 Day Pre-Index Enrollment	6,379	4.21	9.39	1	1	1	1	180	
00-01 years	9	1.00	0.00	1	1	1	1	1	1
02-04 years	19	2.53	6.65	1	1	1	1	30	
05-09 years	21	4.95	9.31	1	1	1	2	30	
10-14 years	32	2.88	7.12	1	1	1	1	30	
15-18 years	59	3.19	7.39	1	1	1	1	30	
19-21 years	57	2.79	6.64	1	1	1	1	30	
22-44 years	976	4.76	9.80	1	1	1	1	90	
45-64 years	3,149	4.26	9.62	1	1	1	1	180	
65-74 years	1,197	4.16	9.53	1	1	1	1	119	
75+ years	860	3.73	8.21	1	1	1	1	31	
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	0	-	-	-	-	-	-	-	
00-01 years	0	-	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-	-
15-18 years	0	-	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-	-
22-44 years	0	-	-	-	-	-	-	-	-
45-64 years	0	-	-	-	-	-	-	-	-
65-74 years	0	-	-	-	-	-	-	-	-
75+ years	0	-	-	-	-	-	-	-	-
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	12	3.92	8.34	1	1	1	2	30	
00-01 years	0	-	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-	-
15-18 years	0	-	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-	-
22-44 years	6	1.83	2.04	1	1	1	1	6	
45-64 years	5	1.20	0.45	1	1	1	1	2	
65-74 years	1	30.00	-	30	30	30	30	30	

Table 2c. Descriptive statistics of first exposure episode duration, in days, by age group								
Exposures	Total Episodes	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
75+ years	0	-	-	-	-	-	-	-
Non-Oil Agents (Omnipaque) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	8	1.75	1.75	1	1	1	2	6
00-01 years	0	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-
15-18 years	0	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-
22-44 years	5	2.00	2.24	1	1	1	1	6
45-64 years	3	1.33	0.58	1	1	1	2	2
65-74 years	0	-	-	-	-	-	-	-
75+ years	0	-	-	-	-	-	-	-

Table 3a. Descriptive statistics of all exposure episode durations, in days								
Exposures	Total Episodes	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	1	1.00	-	1	1	1	1	1
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	12	3.92	8.34	1	1	1	2	30
Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	10,466,793	1.01	0.16	1	1	1	1	15
Ethiodized Oil, 0 Day Pre-Index Enrollment	2	1.00	0.00	1	1	1	1	1
Non-Oil Agents (All), 0 Day Pre-Index Enrollment	8,603	4.12	9.15	1	1	1	1	180
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	0	-	-	-	-	-	-	-
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	12	3.92	8.34	1	1	1	2	30
Non-Oil Agents (Omnipaque) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	8	1.75	1.75	1	1	1	2	6

Table 3b. Descriptive statistics of all exposure episode durations, in days, by sex

Exposures	Total Episodes	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	1	1.00	-	1	1	1	1	1
Female	1	1.00	-	1	1	1	1	1
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	12	3.92	8.34	1	1	1	2	30
Female	12	3.92	8.34	1	1	1	2	30
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-
Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	10,466,793	1.01	0.16	1	1	1	1	15
Female	10,459,091	1.01	0.16	1	1	1	1	15
Male	7,702	1.01	0.10	1	1	1	1	4
Other	0	-	-	-	-	-	-	-
Ethiodized Oil, 0 Day Pre-Index Enrollment	2	1.00	0.00	1	1	1	1	1
Female	2	1.00	0.00	1	1	1	1	1
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-
Non-Oil Agents (All), 0 Day Pre-Index Enrollment	8,603	4.12	9.15	1	1	1	1	180
Female	5,031	4.07	8.71	1	1	1	1	60
Male	3,572	4.20	9.73	1	1	1	1	180
Other	0	-	-	-	-	-	-	-
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	12	3.92	8.34	1	1	1	2	30
Female	12	3.92	8.34	1	1	1	2	30
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-
Non-Oil Agents (Omnipaque) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	8	1.75	1.75	1	1	1	2	6
Female	8	1.75	1.75	1	1	1	2	6
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-

Table 3c. Descriptive statistics of all exposure episode durations, in days, by age group								
Exposures	Total Episodes	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	1	1.00	-	1	1	1	1	1
00-01 years	0	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-
15-18 years	0	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-
22-44 years	1	1.00	-	1	1	1	1	1
45-64 years	0	-	-	-	-	-	-	-
65-74 years	0	-	-	-	-	-	-	-
75+ years	0	-	-	-	-	-	-	-
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	12	3.92	8.34	1	1	1	2	30
00-01 years	0	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-
15-18 years	0	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-
22-44 years	6	1.83	2.04	1	1	1	1	6
45-64 years	5	1.20	0.45	1	1	1	1	2
65-74 years	1	30.00	-	30	30	30	30	30
75+ years	0	-	-	-	-	-	-	-
Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	10,466,793	1.01	0.16	1	1	1	1	15
00-01 years	207	1.00	0.00	1	1	1	1	1
02-04 years	157	1.01	0.08	1	1	1	1	2
05-09 years	447	1.00	0.00	1	1	1	1	1
10-14 years	9,856	1.01	0.09	1	1	1	1	3
15-18 years	166,174	1.01	0.11	1	1	1	1	6
19-21 years	331,331	1.01	0.11	1	1	1	1	9
22-44 years	6,593,370	1.02	0.19	1	1	1	1	15
45-64 years	3,101,927	1.00	0.06	1	1	1	1	9
65-74 years	189,253	1.00	0.04	1	1	1	1	2
75+ years	74,071	1.00	0.04	1	1	1	1	2
Ethiodized Oil, 0 Day Pre-Index Enrollment	2	1.00	0.00	1	1	1	1	1
00-01 years	0	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-



Table 3c. Descriptive statistics of all exposure episode durations, in days, by age group

Exposures	Total Episodes	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
15-18 years	0	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-
22-44 years	2	1.00	0.00	1	1	1	1	1
45-64 years	0	-	-	-	-	-	-	-
65-74 years	0	-	-	-	-	-	-	-
75+ years	0	-	-	-	-	-	-	-
Non-Oil Agents (All), 0 Day Pre-Index Enrollment	8,603	4.12	9.15	1	1	1	1	180
00-01 years	27	1.00	0.00	1	1	1	1	1
02-04 years	57	2.54	6.53	1	1	1	1	30
05-09 years	46	3.46	7.64	1	1	1	1	30
10-14 years	55	4.22	9.11	1	1	1	1	30
15-18 years	88	3.80	8.39	1	1	1	1	30
19-21 years	73	2.41	5.90	1	1	1	1	30
22-44 years	1,162	4.58	9.52	1	1	1	1	90
45-64 years	4,211	4.21	9.42	1	1	1	1	180
65-74 years	1,739	4.05	9.17	1	1	1	1	119
75+ years	1,145	3.72	8.15	1	1	1	1	31
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	0	-	-	-	-	-	-	-
00-01 years	0	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-
15-18 years	0	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-
22-44 years	0	-	-	-	-	-	-	-
45-64 years	0	-	-	-	-	-	-	-
65-74 years	0	-	-	-	-	-	-	-
75+ years	0	-	-	-	-	-	-	-
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	12	3.92	8.34	1	1	1	2	30
00-01 years	0	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-
15-18 years	0	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-
22-44 years	6	1.83	2.04	1	1	1	1	6
45-64 years	5	1.20	0.45	1	1	1	1	2
65-74 years	1	30.00	-	30	30	30	30	30

Table 3c. Descriptive statistics of all exposure episode durations, in days, by age group								
Exposures	Total Episodes	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
75+ years	0	-	-	-	-	-	-	-
Non-Oil Agents (Omnipaque) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	8	1.75	1.75	1	1	1	2	6
00-01 years	0	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-
15-18 years	0	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-
22-44 years	5	2.00	2.24	1	1	1	1	6
45-64 years	3	1.33	0.58	1	1	1	2	2
65-74 years	0	-	-	-	-	-	-	-
75+ years	0	-	-	-	-	-	-	-

Table 4a. Descriptive statistics of days supplied per dispensing								
Exposures	Total Dispensings	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	1	1.00	-	1	1	1	1	1
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	12	3.92	8.34	1	1	1	2	30
Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	11,498,166	1.00	0.00	1	1	1	1	1
Ethiodized Oil, 0 Day Pre-Index Enrollment	2	1.00	0.00	1	1	1	1	1
Non-Oil Agents (All), 0 Day Pre-Index Enrollment	8,637	4.11	8.94	1	1	1	1	100
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	0	-	-	-	-	-	-	-
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	12	3.92	8.34	1	1	1	2	30
Non-Oil Agents (Omnipaque) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	8	1.75	1.75	1	1	1	2	6

Table 4b. Descriptive statistics of days supplied per dispensing, by sex								
Exposures	Total Dispensings	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	1	1.00	-	1	1	1	1	1
Female	1	1.00	-	1	1	1	1	1
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	12	3.92	8.34	1	1	1	2	30
Female	12	3.92	8.34	1	1	1	2	30
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-
Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	11,498,166	1.00	0.00	1	1	1	1	1
Female	11,489,816	1.00	0.00	1	1	1	1	1
Male	8,350	1.00	0.00	1	1	1	1	1
Other	0	-	-	-	-	-	-	-
Ethiodized Oil, 0 Day Pre-Index Enrollment	2	1.00	0.00	1	1	1	1	1
Female	2	1.00	0.00	1	1	1	1	1
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-
Non-Oil Agents (All), 0 Day Pre-Index Enrollment	8,637	4.11	8.94	1	1	1	1	100
Female	5,050	4.05	8.63	1	1	1	1	60
Male	3,587	4.18	9.37	1	1	1	1	100
Other	0	-	-	-	-	-	-	-
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	12	3.92	8.34	1	1	1	2	30
Female	12	3.92	8.34	1	1	1	2	30
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-
Non-Oil Agents (Omnipaque) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	8	1.75	1.75	1	1	1	2	6
Female	8	1.75	1.75	1	1	1	2	6
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-

Table 4c. Descriptive statistics of days supplied per dispensing, by age group								
Exposures	Total Dispensings	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	1	1.00	-	1	1	1	1	1
00-01 years	0	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-
15-18 years	0	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-
22-44 years	1	1.00	-	1	1	1	1	1
45-64 years	0	-	-	-	-	-	-	-
65-74 years	0	-	-	-	-	-	-	-
75+ years	0	-	-	-	-	-	-	-
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	12	3.92	8.34	1	1	1	2	30
00-01 years	0	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-
15-18 years	0	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-
22-44 years	6	1.83	2.04	1	1	1	1	6
45-64 years	5	1.20	0.45	1	1	1	1	2
65-74 years	1	30.00	-	30	30	30	30	30
75+ years	0	-	-	-	-	-	-	-
Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	11,498,166	1.00	0.00	1	1	1	1	1
00-01 years	220	1.00	0.00	1	1	1	1	1
02-04 years	169	1.00	0.00	1	1	1	1	1
05-09 years	469	1.00	0.00	1	1	1	1	1
10-14 years	10,248	1.00	0.00	1	1	1	1	1
15-18 years	176,555	1.00	0.00	1	1	1	1	1
19-21 years	352,721	1.00	0.00	1	1	1	1	1
22-44 years	7,410,965	1.00	0.00	1	1	1	1	1
45-64 years	3,274,989	1.00	0.00	1	1	1	1	1
65-74 years	195,502	1.00	0.00	1	1	1	1	1
75+ years	76,328	1.00	0.00	1	1	1	1	1
Ethiodized Oil, 0 Day Pre-Index Enrollment	2	1.00	0.00	1	1	1	1	1
00-01 years	0	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-

Table 4c. Descriptive statistics of days supplied per dispensing, by age group									
Exposures	Total Dispensings	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum	
15-18 years	0	-	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-	-
22-44 years	2	1.00	0.00	1	1	1	1	1	1
45-64 years	0	-	-	-	-	-	-	-	-
65-74 years	0	-	-	-	-	-	-	-	-
75+ years	0	-	-	-	-	-	-	-	-
Non-Oil Agents (All), 0 Day Pre-Index Enrollment	8,637	4.11	8.94	1	1	1	1	100	
00-01 years	27	1.00	0.00	1	1	1	1	1	1
02-04 years	57	2.54	6.53	1	1	1	1	30	
05-09 years	47	3.38	7.57	1	1	1	1	30	
10-14 years	56	4.14	9.04	1	1	1	1	30	
15-18 years	88	3.80	8.39	1	1	1	1	30	
19-21 years	73	2.41	5.90	1	1	1	1	30	
22-44 years	1,168	4.57	9.49	1	1	1	1	90	
45-64 years	4,225	4.20	9.17	1	1	1	1	100	
65-74 years	1,747	4.03	8.82	1	1	1	1	90	
75+ years	1,149	3.71	8.10	1	1	1	1	30	
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	0	-	-	-	-	-	-	-	
00-01 years	0	-	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-	-
15-18 years	0	-	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-	-
22-44 years	0	-	-	-	-	-	-	-	-
45-64 years	0	-	-	-	-	-	-	-	-
65-74 years	0	-	-	-	-	-	-	-	-
75+ years	0	-	-	-	-	-	-	-	-
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	12	3.92	8.34	1	1	1	2	30	
00-01 years	0	-	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-	-
15-18 years	0	-	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-	-
22-44 years	6	1.83	2.04	1	1	1	1	6	
45-64 years	5	1.20	0.45	1	1	1	1	2	
65-74 years	1	30.00	-	30	30	30	30	30	

Table 4c. Descriptive statistics of days supplied per dispensing, by age group								
Exposures	Total Dispensings	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
75+ years	0	-	-	-	-	-	-	-
Non-Oil Agents (Omnipaque) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	8	1.75	1.75	1	1	1	2	6
00-01 years	0	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-
15-18 years	0	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-
22-44 years	5	2.00	2.24	1	1	1	1	6
45-64 years	3	1.33	0.58	1	1	1	2	2
65-74 years	0	-	-	-	-	-	-	-
75+ years	0	-	-	-	-	-	-	-

Table 5a. Descriptive statistics of the length of all gaps between treatment episodes, in days								
Exposures	Total Gaps	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	1	978.00	-	978	978	978	978	978
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	12	475.17	472.86	55	107	287	827	1,423
Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	10,466,793	474.83	572.61	0	72	268	653	3,285
Ethiodized Oil, 0 Day Pre-Index Enrollment	2	1375.00	561.44	978	978	1375	1772	1,772
Non-Oil Agents (All), 0 Day Pre-Index Enrollment	8,603	453.41	461.50	0	109	293	658	3,107
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	0	-	-	-	-	-	-	-
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	12	475.17	472.86	55	107	287	827	1,423
Non-Oil Agents (Omnipaque) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	8	353.38	329.06	55	89	262	565	942

Table 5b. Descriptive statistics of the length of all gaps between treatment episodes, in days, by sex								
Exposures	Total Gaps	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	1	978.00	-	978	978	978	978	978
Female	1	978.00	-	978	978	978	978	978
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	12	475.17	472.86	55	107	287	827	1,423
Female	12	475.17	472.86	55	107	287	827	1,423
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-
Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	10,466,793	474.83	572.61	0	72	268	653	3,285
Female	10,459,091	474.86	572.64	0	72	268	653	3,285
Male	7,702	437.38	535.71	0	75	257	590	3,280
Other	0	-	-	-	-	-	-	-
Ethiodized Oil, 0 Day Pre-Index Enrollment	2	1375.00	561.44	978	978	1375	1772	1,772
Female	2	1375.00	561.44	978	978	1375	1772	1,772
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-
Non-Oil Agents (All), 0 Day Pre-Index Enrollment	8,603	453.41	461.50	0	109	293	658	3,107
Female	5,031	461.14	463.90	0	112	303	667	3,107
Male	3,572	442.53	457.94	0	105	283	646	3,071
Other	0	-	-	-	-	-	-	-
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	12	475.17	472.86	55	107	287	827	1,423
Female	12	475.17	472.86	55	107	287	827	1,423
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-
Non-Oil Agents (Omnipaque) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	8	353.38	329.06	55	89	262	565	942
Female	8	353.38	329.06	55	89	262	565	942
Male	0	-	-	-	-	-	-	-
Other	0	-	-	-	-	-	-	-

Table 5c. Descriptive statistics of the length of all gaps between treatment episodes, in days, by age group								
Exposures	Total Gaps	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	1	978.00	-	978	978	978	978	978
00-01 years	0	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-
15-18 years	0	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-
22-44 years	1	978.00	-	978	978	978	978	978
45-64 years	0	-	-	-	-	-	-	-
65-74 years	0	-	-	-	-	-	-	-
75+ years	0	-	-	-	-	-	-	-
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	12	475.17	472.86	55	107	287	827	1,423
00-01 years	0	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-
15-18 years	0	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-
22-44 years	6	402.67	358.96	55	104	302	712	942
45-64 years	5	635.40	616.71	73	135	388	1158	1,423
65-74 years	1	109.00	-	109	109	109	109	109
75+ years	0	-	-	-	-	-	-	-
Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	10,466,793	474.83	572.61	0	72	268	653	3,285
00-01 years	207	465.53	624.48	0	83	236	577	3,016
02-04 years	157	634.07	712.33	0	109	345	942	2,994
05-09 years	447	746.29	711.52	1	198	538	1077	3,057
10-14 years	9,856	670.99	687.99	0	150	433	964	3,285
15-18 years	166,174	533.35	583.05	0	112	325	741	3,282
19-21 years	331,331	464.08	497.46	0	95	285	662	3,274
22-44 years	6,593,370	406.05	525.48	0	47	207	555	3,285
45-64 years	3,101,927	601.59	637.23	0	144	377	827	3,285
65-74 years	189,253	654.17	652.05	0	174	408	932	3,283
75+ years	74,071	719.97	688.69	0	184	469	1065	3,280
Ethiodized Oil, 0 Day Pre-Index Enrollment	2	1375.00	561.44	978	978	1375	1772	1,772
00-01 years	0	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-

Table 5c. Descriptive statistics of the length of all gaps between treatment episodes, in days, by age group								
Exposures	Total Gaps	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
15-18 years	0	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-
22-44 years	2	1375.00	561.44	978	978	1375	1772	1,772
45-64 years	0	-	-	-	-	-	-	-
65-74 years	0	-	-	-	-	-	-	-
75+ years	0	-	-	-	-	-	-	-
Non-Oil Agents (All), 0 Day Pre-Index Enrollment	8,603	453.41	461.50	0	109	293	658	3,107
00-01 years	27	214.33	354.78	22	44	116	195	1,795
02-04 years	57	408.79	630.60	2	96	188	304	3,071
05-09 years	46	365.41	451.88	3	65	133	575	1,760
10-14 years	55	472.18	610.53	10	79	205	682	2,702
15-18 years	88	550.18	595.27	3	97	313	807	2,769
19-21 years	73	585.34	559.16	0	86	444	993	2,005
22-44 years	1,162	589.67	530.39	0	157	445	858	3,107
45-64 years	4,211	485.02	489.56	0	115	319	704	2,979
65-74 years	1,739	339.53	331.26	0	92	213	495	2,533
75+ years	1,145	366.49	345.34	0	104	245	540	2,198
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	0	-	-	-	-	-	-	-
00-01 years	0	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-
15-18 years	0	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-
22-44 years	0	-	-	-	-	-	-	-
45-64 years	0	-	-	-	-	-	-	-
65-74 years	0	-	-	-	-	-	-	-
75+ years	0	-	-	-	-	-	-	-
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	12	475.17	472.86	55	107	287	827	1,423
00-01 years	0	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-
15-18 years	0	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-
22-44 years	6	402.67	358.96	55	104	302	712	942
45-64 years	5	635.40	616.71	73	135	388	1158	1,423
65-74 years	1	109.00	-	109	109	109	109	109

Table 5c. Descriptive statistics of the length of all gaps between treatment episodes, in days, by age group								
Exposures	Total Gaps	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
75+ years	0	-	-	-	-	-	-	-
Non-Oil Agents (Omnipaque) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	8	353.38	329.06	55	89	262	565	942
00-01 years	0	-	-	-	-	-	-	-
02-04 years	0	-	-	-	-	-	-	-
05-09 years	0	-	-	-	-	-	-	-
10-14 years	0	-	-	-	-	-	-	-
15-18 years	0	-	-	-	-	-	-	-
19-21 years	0	-	-	-	-	-	-	-
22-44 years	5	446.20	383.21	55	104	418	712	942
45-64 years	3	198.67	166.87	73	73	135	388	388
65-74 years	0	-	-	-	-	-	-	-
75+ years	0	-	-	-	-	-	-	-



Table 6. Counts of reason for censoring, all episodes and first episode								
	Total		Disenrollment		Evidence of death		Episode end	
	N	%	N	%	N	%	N	%
Exposures								
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	1	100.0	0	0.0	0	0.0	1	100.0
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	12	100.0	0	0.0	0	0.0	12	100.0
Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	10,466,793	100.0	9,009	0.1	5	0.0	10,466,793	100.0
Ethiodized Oil, 0 Day Pre-Index Enrollment	2	100.0	0	0.0	0	0.0	2	100.0
Non-Oil Agents (All), 0 Day Pre-Index Enrollment	8,603	100.0	31	0.4	2	0.0	8,601	100.0
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	0	-	0	-	0	-	0	-
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	12	100.0	0	0.0	0	0.0	12	100.0
Non-Oil Agents (Omnipaque) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	8	100.0	0	0.0	0	0.0	8	100.0
Patients' First Episode								
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	1	100.0	0	0.0	0	0.0	1	100.0
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	12	100.0	0	0.0	0	0.0	12	100.0
Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	5,965,597	100.0	5,059	0.1	5	0.0	5,965,597	100.0
Ethiodized Oil, 0 Day Pre-Index Enrollment	2	100.0	0	0.0	0	0.0	2	100.0
Non-Oil Agents (All), 0 Day Pre-Index Enrollment	6,379	100.0	25	0.4	2	0.0	6,377	100.0
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	0	-	0	-	0	-	0	-
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	12	100.0	0	0.0	0	0.0	12	100.0
Non-Oil Agents (Omnipaque) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	8	100.0	0	0.0	0	0.0	8	100.0

Table 7. Cohort Attrition Table	
Attrition Criteria	Members
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	140,150,000 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y during the query period	111,780,000 (79.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	111,780,000 (79.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y during the query period	111,780,000 (79.8%)
Exclusion - Members must satisfy the age range condition within the query period	111,780,000 (79.8%)
Exclusion - Members must meet chart availability criterion within the query period	111,780,000 (79.8%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	111,780,000 (79.8%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	2 (0.0%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	2 (0.0%)
Exclusion - Members must have at least one episode defining index claim during the query period	2 (0.0%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	2 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	2 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	2 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	1 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	1 (0.0%)
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	140,150,000 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y during the query period	111,780,000 (79.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	111,780,000 (79.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y during the query period	111,780,000 (79.8%)
Exclusion - Members must satisfy the age range condition within the query period	111,780,000 (79.8%)
Exclusion - Members must meet chart availability criterion within the query period	111,780,000 (79.8%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	111,780,000 (79.8%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	6,379 (0.0%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	6,379 (0.0%)
Exclusion - Members must have at least one episode defining index claim during the query period	6,379 (0.0%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	6,379 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	6,379 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	6,379 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	12 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	12 (0.0%)
Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	140,150,000 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y during the query period	111,780,000 (79.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	111,780,000 (79.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y during the query period	111,780,000 (79.8%)
Exclusion - Members must satisfy the age range condition within the query period	111,780,000 (79.8%)

Table 7. Cohort Attrition Table	
Attrition Criteria	Members
Exclusion - Members must meet chart availability criterion within the query period	111,780,000 (79.8%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	111,780,000 (79.8%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	5,965,597 (4.3%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	5,965,597 (4.3%)
Exclusion - Members must have at least one episode defining index claim during the query period	5,965,597 (4.3%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	5,965,597 (4.3%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	5,965,597 (4.3%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	5,965,597 (4.3%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	5,965,597 (4.3%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	5,965,597 (4.3%)
Ethiodized Oil, 0 Day Pre-Index Enrollment	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	140,150,000 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y during the query period	111,780,000 (79.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	111,780,000 (79.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y during the query period	111,780,000 (79.8%)
Exclusion - Members must satisfy the age range condition within the query period	111,780,000 (79.8%)
Exclusion - Members must meet chart availability criterion within the query period	111,780,000 (79.8%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	111,780,000 (79.8%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	2 (0.0%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	2 (0.0%)
Exclusion - Members must have at least one episode defining index claim during the query period	2 (0.0%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	2 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	2 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	2 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	2 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	2 (0.0%)
Non-Oil Agents (All), 0 Day Pre-Index Enrollment	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	140,150,000 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y during the query period	111,780,000 (79.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	111,780,000 (79.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y during the query period	111,780,000 (79.8%)
Exclusion - Members must satisfy the age range condition within the query period	111,780,000 (79.8%)
Exclusion - Members must meet chart availability criterion within the query period	111,780,000 (79.8%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	111,780,000 (79.8%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	6,379 (0.0%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	6,379 (0.0%)
Exclusion - Members must have at least one episode defining index claim during the query period	6,379 (0.0%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	6,379 (0.0%)

Table 7. Cohort Attrition Table	
Attrition Criteria	Members
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	6,379 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	6,379 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	6,379 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	6,379 (0.0%)
Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	140,150,000 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y during the query period	111,780,000 (79.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	111,780,000 (79.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y during the query period	111,780,000 (79.8%)
Exclusion - Members must satisfy the age range condition within the query period	111,780,000 (79.8%)
Exclusion - Members must meet chart availability criterion within the query period	111,780,000 (79.8%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	111,780,000 (79.8%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	2 (0.0%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	2 (0.0%)
Exclusion - Members must have at least one episode defining index claim during the query period	2 (0.0%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	2 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	0 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	0 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	0 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	0 (0.0%)
Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	140,150,000 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y during the query period	111,780,000 (79.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	111,780,000 (79.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y during the query period	111,780,000 (79.8%)
Exclusion - Members must satisfy the age range condition within the query period	111,780,000 (79.8%)
Exclusion - Members must meet chart availability criterion within the query period	111,780,000 (79.8%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	111,780,000 (79.8%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	6,379 (0.0%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	6,379 (0.0%)
Exclusion - Members must have at least one episode defining index claim during the query period	6,379 (0.0%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	6,379 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	5,804 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	5,804 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	12 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	12 (0.0%)
Non-Oil Agents (Omnipaque) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	140,150,000 (100.0%)

Table 7. Cohort Attrition Table	Attrition Criteria	Members
	Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y during the query period	111,780,000 (79.8%)
	Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	111,780,000 (79.8%)
	Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y during the query period	111,780,000 (79.8%)
	Exclusion - Members must satisfy the age range condition within the query period	111,780,000 (79.8%)
	Exclusion - Members must meet chart availability criterion within the query period	111,780,000 (79.8%)
	Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	111,780,000 (79.8%)
	Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	5,310 (0.0%)
	Exclusion - Members must have at least one cohort episode beginning within the age range condition	5,310 (0.0%)
	Exclusion - Members must have at least one episode defining index claim during the query period	5,310 (0.0%)
	Exclusion - Members must have at least one cohort episode incident with respect to other criteria	5,310 (0.0%)
	Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	5,310 (0.0%)
	Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	5,310 (0.0%)
	Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	8 (0.0%)
	Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	8 (0.0%)

Appendix A. Dates of Available Data for Each Data Partner (DP) up to Request End Date (05/07/2020) as of Query Distribution Date

Data Partner (Masked)	Start Date	End Date
DP01	01/01/2010	12/31/2018

Appendix B. Specifications Used to Define Parameters in this Query

Global Values

Enrollment Criteria: **Medical and Drug Coverage**

Enrollment Gap (Days): **45**

Age Groups (Years): **00-01, 02-04, 05-09, 10-14, 15-18, 19-21, 22-44, 45-64, 65-74, 75+**

Query Period: **01/01/2010-12/31/2018**

Baseline Characteristics Table: **No**

Baseline Evaluation Window (Day):

#	Cohort Name	Index Exposure	Pre-Index Enrollment Period (Days)	Washout Period (Days)	Treatment Episode Gap (Days)	Treatment Episode Extension (Days)	Inclusion/Exclusion	Criteria	Criteria Definition	Evaluation Period Start (Day)	Evaluation Period End (Day)
1	Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	Ethiodized Oil ^[1]	0	0	0	0	Inclusion	HSG	HSG ^[2]	0	0
2	Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	Non Oil Agents ^[3]	0	0	0	0	Inclusion	HSG	HSG ^[4]	0	0
3	Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	HSG Procedures (No Exposure) ^[5]	0	0	0	0	--	--	--	--	--
4	Ethiodized Oil, 0 Day Pre-Index Enrollment	Ethiodized Oil ^[6]	0	0	0	0	--	--	--	--	--
5	Non-Oil Agents (All), 0 Day Pre-Index Enrollment	Non Oil Agents ^[7]	0	0	0	0	--	--	--	--	--
6	Ethiodized Oil and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	Ethiodized Oil ^[8]	180	0	0	0	Inclusion	HSG	HSG ^[9]	0	0
7	Non-Oil Agents (All) and Hysterosalpingography (HSG) Procedures, 180 Day Pre-Index Enrollment	Non Oil Agents ^[10]	180	0	0	0	Inclusion	HSG	HSG ^[11]	0	0
8	Non-Oil Agents (Omnipaque) and Hysterosalpingography (HSG) Procedures, 0 Day Pre-Index Enrollment	Omnipaque ^[12]	0	0	0	0	Inclusion	HSG	HSG ^[13]	0	0

ICD-9, ICD-10, HCPCS AND CPT are provided by Optum360
NDCs are checked against First Data Bank's MedKnowledge.

Appendix of Generic Names and Chronic Conditions

[1] See Appendix C

[2] See Appendix E

[3] See Appendix C

[4] See Appendix E

[5] See Appendix D

[6] See Appendix C

[7] See Appendix C

[8] See Appendix C

[9] See Appendix E

[10] See Appendix C

[11] See Appendix E

[12] See Appendix C

[13] See Appendix E

Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Module

Age Groups - Age groups of members included in the cohort. Strata also used for reporting purposes.

Ambulatory Visit (AV) - A care setting value including visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Baseline Characteristics Table - Optional table containing general characteristics of study population, including background rates of 27 chronic conditions from the CMS Chronic Condition Warehouse (see above if table requested). Users define an evaluation period for the presence of baseline characteristics.

Care Setting - Type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Charlson/Elixhauser Combined Comorbidity Score - Calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Cohort Definition - Cohort includes all valid exposure episodes during the query period. Only the first valid episode's incidence is assessed using the washout period.

Emergency Department (ED) - A care setting value including ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Enrollment Criteria - Type of coverage required during enrollment period. By default, all patients must have medical and drug coverage.

Enrollment Gap - Allowed gap between coverage periods.

Episodes - Treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Inclusion/Exclusion - Contains the comprehensive set of codes used to define additional cohort inclusion and/or exclusion criteria (e.g., restrict cohort to individuals with evidence of a pre-existing condition 183 days before the index date). Criteria could be defined with complex algorithms (e.g., diagnosis codes and drug codes) defined under Criteria Definition.

Inpatient Hospital Stay (IP) - A care setting value including all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - A care setting value including hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - A care setting value including other non-overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Principal Diagnosis (PDX) - Diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '' = blank. Along with the Care Setting values, forms the CareSetting/PDX parameter.

Query Period - The period of time which patients can contribute index-defining exposure/events. Data prior to the start date may be used to determine enrollment, washout, and other cohort inclusion criteria.

Treatment Episode Extension - The episode extension adds the selected number of days to the end of an episode to count as exposed time.

Treatment Episode Gap - The maximum number of days allowed between two dispensings to consider them part of the same episode.

Washout Period - The period before an exposure episode during which an individual cannot have evidence of incidence-defining criteria.

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Index Exposure in this Request

Generic Name	Brand Name
Ethiodized Oil	
ethiodized oil	Lipiodol
ethiodized oil	Ethiodol
Non-Oil Agents (Non-Omnipaque)	
iothalamate meglumine	Cysto-Conray II
iothalamate meglumine	Conray-30
iothalamate meglumine	Conray
diatrizoate meglumine/diatrizoate sodium	MD-76 R
ioversol	Optiray 320
ioversol	Optiray 240
ioversol	Optiray 300
ioversol	Optiray 350
iothalamate meglumine	Conray-43
diatrizoate meglumine/diatrizoate sodium	MD-Gastroview
diatrizoate meglumine	Cystografin
iodipamide meglumine	Cholografin Meglumine
diatrizoate meglumine/diatrizoate sodium	Gastrografen
iodipamide meglumine/diatrizoate meglumine	Sinografin
diatrizoate meglumine	Reno-Dip
iopamidol	Isovue-200
iopamidol	Isovue-300
iopamidol	Isovue-370
iopamidol	Isovue-250
diatrizoate meglumine	Cystografin-Dilute
iopamidol	Isovue-M 200
iopamidol	Isovue-M 300
diatrizoate meglumine	Hypaque-Cysto
diatrizoate meglumine	Hypaque Meglumine
diatrizoate sodium	Hypaque Sodium
iodixanol	Visipaque
iopromide	Ultravist
ioxilan	Oxilan-350
Diatrizoate meglumine/diatrizoate sodium	Hypaque-76
Non-Oil Agents (Omnipaque)	
iohexol	Omnipaque 140
iohexol	Omnipaque 180
iohexol	Omnipaque 240
iohexol	Omnipaque Rediflo 240
iohexol	Omnipaque Rediflo 300
iohexol	Omnipaque 300
iohexol	Omnipaque Rediflo 350
iohexol	Omnipaque 350
iohexol	Omnipaque
iohexol	iohexol

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4) Codes Used to Define Exposures of Interest in this Request

Code	Description	Code Category	Code Type
Hysterosalpingography (HSG)			
74740	Hysterosalpingography, radiological supervision and interpretation	Procedure	CPT-4
58340	Catheterization and introduction of saline or contrast material for saline infusion sonohysterography (SIS) or hysterosalpingography	Procedure	CPT-4
76831	Saline infusion sonohysterography (SIS), including color flow Doppler, when performed	Procedure	CPT-4
76830	Ultrasound, transvaginal	Procedure	CPT-4
58345	Transcervical introduction of fallopian tube catheter for diagnosis and/or re-establishing patency (any method), with or without hysterosalpingography	Procedure	CPT-4

Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4) Codes Used to Define Inclusion Criteria in this Request

Code	Description	Code Category	Code Type
Hysterosalpingography (HSG)			
74740	Hysterosalpingography, radiological supervision and interpretation	Procedure	CPT-4
58340	Catheterization and introduction of saline or contrast material for saline infusion sonohysterography (SIS) or hysterosalpingography	Procedure	CPT-4
76831	Saline infusion sonohysterography (SIS), including color flow Doppler, when performed	Procedure	CPT-4
76830	Ultrasound, transvaginal	Procedure	CPT-4
58345	Transcervical introduction of fallopian tube catheter for diagnosis and/or re-establishing patency (any method), with or without hysterosalpingography	Procedure	CPT-4